About Shionogi

Who we are

Shionogi Europe is a new healthcare company, founded 140 years after the organisation was founded (1878) by Gisaburo Shiono SR. in Doshomachi, Osaka, Japan. Today the headquarters of Shionogi & Co., Ltd are still in Osaka however the company has grown to become a major research-driven pharmaceutical company dedicated to placing the highest value on patient care.

In 2012, Shionogi Europe headquarters launched in London, United Kingdom which marked the beginning of a new era for the organisation.

From our original office in London, we have grown the organisation across the region, with our European registered office in the Netherlands, managing a development and commercial establishment in London, with commercial affiliates in Germany, Italy, Spain and the UK.

At Shionogi Europe we are committed to working differently and more closely with patients and the communities we serve, across Europe, the Middle East and Africa (EMEA). It is our ambition to be a leader in healthcare through the discovery and supply of medicines that offer the greatest level of satisfaction to patients, their families and healthcare providers, and that improve quality of life.

We are guided by a simple but powerful principle: follow the needs of the patient and the community that surrounds them. This means ensuring that the real-life challenges patients face everyday remain the primary purpose behind R&D, which we believe is a more encouraging way to create clinically-meaningful therapies. No-one at Shionogi is separated from the patient by more than one degree: we listen closely to patients, which is how we make a real difference.

We hope our patient-first approach lays strong foundations on which to build a centre of excellence in R&D. As a research-led organisation, we are defined by a distinct openness and close partnership approach to creating vaccines and medicines spanning pain, infectious diseases, metabolic disorders, women’s health and oncology.

Our development approach goes hand in hand with the collaborative drug discovery process at the heart of Shionogi. We have an impressive track record of fostering long-term industry partnerships built on trust and a mutual ambition to develop innovative medicines that address unmet medical needs. The breadth of our collaboration network demonstrates this commitment, alongside the Shionogi Science Program (SSP), which aims to provide support to researchers driven by the discovery of innovative ideas for drug development and technology, enabling them to search for the answer to their questions.

You won’t find a page on corporate social responsibility on this website. We believe that this should be inherent in everything we do and we are very conscious of our social and civic responsibilities towards patients, their families, healthcare providers and broader communities.

If you have a question that you can’t find the answer to on this website, just say hello and we’ll get back to you.